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Pharmacologic toxicities are common and range from mild to life-threatening. The aim of this study is to review and update the
data on the role of renal replacement therapy (RRT) in the management of various pharmacologic poisonings. We aim to provide
a focused review on the role of RRT in the management of pharmacological toxicities. Relevant publications were searched in
MEDLINE with the following search terms alone or in combination: pharmacologic toxicity, hemodialysis, hemofiltration, renal
replacement therapy, toxicology, poisonings, critical illness, and intensive care.The studies showed that a pharmacologic substance
should meet several prerequisites to be deemed dialyzable. These variables include having a low molecular weight (<500Da)
and low degree of protein binding (<80%), being water-soluble, and having a low volume of distribution (<1 L/kg). RRT should
be strongly considered in critically ill patients presenting with toxic alcohol ingestion, salicylate overdose, severe valproic acid
toxicity, metformin overdose, and lithium poisoning. The role of RRT in other pharmacologic toxicities is less certain and should
be considered on a case-by-case basis.
1. Introduction
Pharmacological substances carry an intrinsic risk of toxicity
as the result of either idiosyncrasy or overdose. For example,
there were 2,188,013 cases of human exposures to various
toxic substances resulting in 20,749 cases of serious adverse
reactions and 1,552 deaths in 2013 [1]. In such cases, hemodial-
ysis was used in more than 2,290 cases [2]. In the year 2014,
pharmaceutical toxicities were responsible for 61.4% of cases
and nonpharmacological exposures accounted for 14.1% of
registered cases in 2014 [2].
The goal of this article is to review the data and evidence
on the use of RRT in the management of certain pharma-
cologic overdoses. First, we review and discuss the different
factors thatwould affect dialyzability of drugs and toxins. Sec-
ond, we discuss different extracorporeal treatmentmodalities
with focus on hemodialysis and hemofiltration treatments.
Third, we review the role of RRT in the management of
specific drugs and poisons including toxic alcohols, salicylate,
lithium, metformin, valproic acid, and dabigatran. Lastly, we
discuss the role of RRT in the management of less common
miscellaneous cases of intoxication.
It is important to mention that the management of the
toxicities mentioned above is complex and usually requires
measures in addition to dialysis.
2. Removal of Drugs and Toxins by
Extracorporeal Therapies
The use of extracorporeal techniques to remove toxins is
justified if there is an indication of severe toxicity. The
extent to which a drug is affected by extracorporeal ther-
apies is determined primarily by several physicochemical
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Table 1: Optimal physicochemical properties for extracorporeal
removal of drugs.
Hemodialysis Hemofiltration Hemoperfusion
Molecular
weight <500Da <40KDa <40KDa
Protein binding Low (<80%) Low Low or high
Volume of
distribution <1 L/Kg <1 L/Kg <1 L/Kg
Solubility Water Water Water or lipid
Endogenous
clearance <4mL/Kg/min <4mL/Kg/min <4mL/Kg/min
characteristics of the drug which are summarized in Table 1.
These include molecular size, protein binding, volume of
distribution, water solubility, and endogenous clearance. In
addition to these properties of the drug, technical aspects of
the procedure may also determine the extent to which a drug
is removed [3, 4].
2.1. Molecular Weight. Dialysis is dependent upon the use
of a synthetic dialytic membrane with fixed pore size. The
movement of drugs or other solutes is largely determined
by the size of these molecules in relation to the pore size of
the membrane. As a general rule, smaller molecular weight
substances will pass through the membrane more easily than
larger molecular weight substances.
2.2. Protein Binding. Another important factor determining
drug removal during dialysis is the concentration gradient of
unbound (free) drug across the dialysis membrane. Because
the primary binding proteins for most drugs (mainly albu-
min) are of large molecular size, the drug protein complex
is often unable to cross the dialysis membrane. Drugs with
a high degree of protein binding will have a low plasma
concentration of unbound drug available for dialysis and
therefore lower clearance.
2.3. Volume of Distribution. The efficacy of toxin removal is
also influenced by its theoretical volume of distribution (VD).
A drug with a large VD is distributed widely throughout
tissues and is present in relatively small amounts in the blood.
Factors that contribute to a large VD include a high degree
of lipid solubility and low plasma protein binding. Drugs
with a large volume of distribution (>1 L/kg) are likely to be
minimally dialyzed.
2.4. Water Solubility. The dialyzate used for hemodialysis is
an aqueous solution. In general, drugs with high water
solubility will be dialyzed to a greater extent than those with
high lipid solubility. Highly lipid-soluble drugs tend to be
distributed throughout tissues, and therefore only a small
fraction of the drug is present in plasma and is accessible for
dialysis.
2.5. Endogenous Clearance. This includes renal and nonrenal
(mainly hepatic) clearance of the drug. Dialysis will have a
limited impact if the rate of drug removal is significantly
faster by endogenous routes (>4mL/Kg/min). It is generally
accepted that use of extracorporeal treatment is justified, if
at least 30% can be added to total body clearance by such
treatment.
3. Extracorporeal Treatment Modalities
The extracorporeal techniques most frequently employed
for the removal of toxins are intermittent hemodialysis,
continuous renal replacement therapy, and hemoperfusion.
There are a few reports on the use of molecular adsorbent
recirculating system (MARS) in poisoning, specifically for
those toxins that are strongly protein bound; however, the use
of MARS is limited by its availability, technical applicability,
and high costs.
3.1. Intermittent Hemodialysis. During hemodialysis (HD),
toxins and other solutes are cleared from the blood by
diffusion against a steep concentration gradient through
a semipermeable membrane into dialyzate. In addition to
its specific properties (Table 1), the clearance of a toxic
substance during HD depends also on membrane surface
area and type, as well as on blood and dialyzate flow rates.
HD comes in standard as well as high-efficiency or high-
flux modalities. The major difference is the pore size of
the membrane, the type of membrane, and the amount of
dialyzate flow that occurs. Increasing blood and dialyzate
flow rates can increase the concentration gradient between
blood and dialyzate, thus optimizing the rates of diffusion and
elimination. Clearances can also be enhanced by increasing
dialyzer efficiency or membrane surface area. Larger-solute
removal can be enhanced by increasing dialyzer flux when
intermittentHD is used (for toxins>500 d and up to 10,000 d)
or by switching to hemofiltration, which is usually applied
continuously as discussed later.
Themajor drawback of HD is the risk of rebound toxicity
after cessation of the treatment, due to redistribution of the
toxin between body compartments. Extending the HD ses-
sion beyond 4 hours can to some extent ameliorate rebound;
however, this may not be easily feasible. An alternative or
adjunctive solution is to increase dialysis session frequency
or switch to continuous therapy after initial HD treatment
specifically for substances with higher volume of distribution.
Intermittent HD is usually the first-choice extracorporeal
modality because of its common availability, the rapidity of
toxin removal, and the low molecular weight of the common
agents of poisoning [5].
3.2. Continuous Renal ReplacementTherapy (CRRT). Theuse
of CRRThas become commonpractice in Intensive CareUnit
(ICU) settings during the last 2 decades for treatment of acute
kidney injury. The term CRRT is commonly used to describe
all continuous modalities of hemofiltration. Continuous ven-
ovenous hemofiltration (CVVH) is the most commonly used
of the CRRT modalities, where dialysis occurs by convec-
tive transport. In continuous venovenous hemodiafiltration
(CVVHDF), diffusive transport of molecules is combined
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with convective removal in order to mainly improve the
clearance of small solutes [6].
The main advantage of CRRT is its applicability in hemo-
dynamically unstable patients. It can be easily set up and run
by regular ICU staff, thereby avoiding the need for specially
trained dialysis nurses and technicians.Themembranes used
in CRRT are typically more permeable compared to standard
intermittentHDmembranes.Most high-fluxHDmembranes
allow for the clearance of molecules up to 10,000Da. CRRT
membranes allow for the clearance of molecules as large
as 20,000–40,000Da and therefore would be the preferred
modality for larger toxins removal. Another advantage of
CRRT is the ability to avoid rebound of toxins removed from
intravascular space, due to continuous nature of the proce-
dure and slower rate of clearance, leading to less dramatic
decreases in plasma drug levels and slower reequilibration of
toxins between intracellular and intravascular spaces [5, 7].
Although CRRT gives better longer-term solute clear-
ances (over the course of several days), it is less efficient
in the short term and does not provide the rapidity of
elimination afforded by intermittent HD when minimizing
toxin exposure is a high priority. Other disadvantages of
CRRT include the requirement for intensive anticoagulation
which can place a patient at risk for bleeding and it is more
associated with electrolyte disturbances. Finally, CRRT is not
available at many smaller hospitals, possibly due to high
equipment, training, and staffing costs [4, 8].
There are abundant case reports as well as a few small
case series in the medical literature documenting the use of
CRRT in the treatment of poisonings, but specific techniques
and the clinical outcomes vary considerably. Therefore,
one cannot draw definitive conclusions regarding benefit.
Some patients, particularly those who are hemodynamically
unstable and are not candidates for conventional HD, may
warrant a trial of CRRT. If it is logistically possible, an
ideal combination may be initial use of intermittent HD
for rapid reduction of toxin levels followed by continuous
therapy to ameliorate any postdialysis rebound when this is
predicted. Controlled trials to better clarify the role of CRRT
in treatment of poisonings would be beneficial, though such
studies would be extremely difficult to conduct in this field
[8].
3.3. Hemoperfusion. Hemoperfusion consists of the passage
of anticoagulated blood through a cartridge containing an
adsorbent material such as activated charcoal or a resin. In
order to be removed by hemoperfusion, the toxic substance
must have binding affinity to the sorbent in the cartridge
and a low volume of distribution (Table 1). Water-soluble and
lipid-soluble substanceswithmolecularweights ranging from
100 to 40,000 daltons are well adsorbed with hemoperfusion.
In general, hemoperfusion is preferred to hemodialysis
for the removal of chemicals that are lipid-soluble or are
highly protein bound. However, the advantage of hemoper-
fusion over HD has lessened with the advent of high-flux
dialysis membranes. Additionally, there is generally greater
expertise and availability with respect to hemodialysis than
hemoperfusion [42].
4. Renal Replacement Therapy in
the Management of Specific
Pharmacologic Poisonings
4.1. Toxic Alcohol Ingestion. Methanol, ethylene glycol, di-
ethylene glycol, and isopropyl alcohol (also known as iso-
propanol) are alcohols commonly used in household solu-
tions such as various cleaners, disinfectants, solvents, and
antifreeze solutions as well as machine fluids [43–45]. There
were 52,430 exposures to alcohols resulting in 174 fatalities in
2013 [46].The vast majority of methanol, ethylene glycol, and
isopropyl alcohol toxicities arise either as a result of suicidal
attempts or after drinking the toxic alcohol as a substitute for
ethanol [43]. However, the vast majority of diethylene glycol
toxicities are the result of the introduction of diethylene glycol
into various pharmacologic substances as a substitution for
more expensive and less toxic substances [45].
To understand the basic pathogenesis of methanol, ethy-
lene glycol, diethylene glycol, and isopropyl alcohol toxi-
cities, it is important to briefly review the metabolism in
vivo. When ingested, both methanol and ethylene glycol
undergo an initial biochemical reaction catalyzed by alcohol
dehydrogenase (the same enzyme metabolizing ethanol),
which converts the parent alcohol into formaldehyde and
glycolaldehyde, respectively. The final products of methanol
and ethylene glycol metabolism are formic acid and oxalic
acid, respectively [43]. The metabolism of methanol and
ethylene glycol disrupts cellular energymetabolism leading to
cellular damage [47, 48]. These end products result in classic
features of toxicity such as retinal toxicity caused bymethanol
and renal injury mediated by oxalic acid.
The first step of diethylene glycol metabolism also
involves the alcohol dehydrogenase enzyme which con-
verts diethylene glycol into 2-hydroxyethoxyacetaldehyde
[45]. Aldehyde dehydrogenase enzyme, in turn, converts
2-hydroxyethoxyacetaldehyde into 2-hydroxyethoxyacetic
acid. The pathogenesis of diethylene glycol toxicity was
first believed to involve the in vivo formation of ethylene
glycol as the result of metabolism. However, further ani-
mal studies showed that the major toxic metabolite is 2-
hydroxyethoxyacetic acid and that the metabolic conversion
of diethylene glycol into ethylene glycol does not occur in vivo
[45].
The first step of isopropyl alcohol in vivometabolism also
involves the enzyme alcohol dehydrogenase, which converts
it into acetone. Acetone, in turn, undergoes several interme-
diatemetabolic stepswith the endproduct being glucose [44].
It is important to note that, in the vast majority of cases,
isopropyl alcohol appears to be less toxic than methanol and
ethylene glycol which are associated with greater toxicities
and mortality rates [44, 47, 48].
The clinical presentations of methanol, ethylene glycol,
and isopropyl alcohol overlap and include CNS depression,
alteredmental status, and seizures. Retinal toxicity and blind-
ness are more specific for methanol intoxication, and acute
kidney injury and hypocalcemia are more typical for ethy-
lene glycol intoxication. Laboratory testing and diagnosis of
methanol and ethylene glycol are based on the presence of
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Methanol
Formaldehyde
Formic acid (toxic)
Folic acid
Ethylene glycol
Glycolaldehyde
Glycolic acid
Glyoxylic acid
Oxalic acid (toxic)
Calcium oxalate
Alcohol dehydrogenase
Aldehyde
dehydrogenase
Lactate dehydrogenase
Glycolate oxidase
GlycineTh
iam
ine
Alpha-hydroxy-
beta-ketoadipate
PyridoxineCO2+H2O
+
+
++
+ +
Figure 1: An overview of in vivo methanol and ethylene glycol metabolism.
Alcohol dehydrogenase+
+ Acetone monooxygenase
Acetone monooxygenase+
+ Glyoxylase
Alcohol dehydrogenase +
+Aldehyde
dehydroxygenase
Isopropyl alcohol
Acetone
Acetol
Methylglyoxal
D-Lactate
Glucose
L-Lactate
L-Lactaldehyde Formate+Acetate
L-Propane-1, 2-diol
Figure 2: An overview of in vivo isopropyl alcohol metabolism.
a high anion gap metabolic acidosis, presence of a serum
osmolal gap (a difference between measured osmolality and
calculated osmolality ≥ 10), and measuring the levels of the
toxic alcohols which is used for confirmation (typically these
tests are not time sensitive, and treatment should not be
withheld in any patient suspected of having toxic alcohol
ingestion). Isopropyl alcohol laboratory findings include the
presence of a high serum osmolal gap, presence of ketone
bodies in the blood and/or urine (because of acetone), and
typically the absence of a high anion gap metabolic acidosis.
A brief overview of the in vivo metabolism of methanol and
ethylene glycol is presented in Figure 1 and an overview of
isopropyl alcohol metabolism is presented in Figure 2.
The management of methanol and ethylene glycol poi-
soning includes supportive care, respiratory support if
needed (mechanical ventilation), the use of cofactors to
stimulate formation of less toxic metabolites (see Figures
1 and 2), and the use of either an alcohol dehydrogenase
inhibitor (fomepizole) or ethanol, which work by displacing
the toxic alcohol and preventing it from being metabolized
by alcohol dehydrogenase. Ethanol is less desirable and
should only be used in cases of fomepizole unavailability.
It is important to remember that fomepizole and ethanol
have no effect on the metabolism and clearance of toxic
metabolites such as formic acid and glycolic acid. Therefore,
inhibition of alcohol dehydrogenase will not translate into
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an improved outcome once the parent alcohol has been
metabolized.
RRT should be considered in cases of ongoing hemo-
dynamic instability despite appropriate management and
especially in the presence of severe metabolic acidosis, acute
kidney injury, and target organ damage (retinal toxicity in
methanol and acute kidney injury in ethylene glycol toxicity)
[45, 47]. The small size, low VD, and low protein binding
for these alcohols make them readily dialyzable, making
standard hemodialysis the first-line therapy for extracor-
poreal elimination except in cases where hemodialysis is
not available or in the setting of significant hemodynamic
compromise where CRRT would be indicated [8]. Consen-
sus guidelines recommend hemodialysis when the levels of
parent alcohols exceed 50mg/dL, although some patients
without evidence of target organ damage, acute kidney injury,
and metabolic acidosis may be managed without hemodialy-
sis. Hemodialysis should also be considered in patients with
ethylene glycol poisoning that have a persistent hyperosmolar
state (despite appropriate management) [49] and levels of
glycolic acid above 8mmol/L [50]. It is important to mention
that, in cases of methanol poisoning, hemodialysis enhances
the clearance of methanol (the endogenous clearance of
methanol is slow after alcohol dehydrogenase inhibition)
[48], but it only marginally increases the clearance of formic
acid [9]. Also, hemodialysis may be less costly than therapy
with fomepizole; however, it is essential to remember that
hemodialysis is associated with more complications and
should be limited to patients with clear indications [51]. End
goals of hemodialysis in these patients should be normaliza-
tion of acid base status, resolution of hyperosmolar states,
and a decreased blood level of parent toxic alcohols (less than
25mg/dL). Redistribution of methanol and ethylene glycol
can occur after hemodialysis and the serum electrolytes,
osmolality, and acid base status should be monitored for
additional 12–36 hours after the last hemodialysis treatment
[47, 48].
Literature on the role of hemodialysis in the management
of diethylene glycol is scant [45], and it is unclear whether
the active toxic metabolite is removed by hemodialysis.
Nevertheless, hemodialysis should be considered in patients
with progressive clinical deterioration despite appropriate
care and persistent high anion gap metabolic acidosis.
In cases of isopropyl alcohol toxicity, the role of hemodial-
ysis is less clear [44]. Isopropyl alcohol intoxication generally
has a more favorable outcome compared to methanol and
ethylene glycol poisonings and the vast majority of patients
will improve with supportive therapy and alcohol dehydro-
genase inhibition. In the rare patient with hemodynamic
instability and an isopropyl alcohol level above 4,000mg/dL
(which is usually due to a massive ingestion), hemodialysis
may be considered.
When considering renal replacement therapy in these
patients, it is important to note that both fomepizole and
ethanol are cleared by hemodialysis and the doses of fomepi-
zole and ethanol should be adjusted accordingly.
An overview of the clinical presentations, major labora-
tory findings, general principles of management, and indi-
cations for hemodialysis among patients with toxic alcohol
ingestion is presented in Table 2. A summary of toxic alcohol
pharmacokinetics and the utility of hemodialysis is presented
in Table 3.
4.2. Salicylate Toxicity. Salicylates are a group of pharmaco-
logic agents which includes aspirin, bismuth salicylate, and
local skin preparations such as salicylic acid and methyl
salicylate (topical preparations occasionally cause toxicity if
used excessively or in patients with skin damage leading to
increased absorption) [10, 52, 53].
Analgesics including aspirin are the most common eti-
ology of all drug poisonings in the USA, and salicylate
poisoning caused 34 out of 2,113 deaths due to poisonings
reported in 2013 [51]. The major mechanism of action of
aspirin is via inhibition of cyclooxygenase enzyme resulting
in decreased production of thromboxane A2 and various
prostaglandins [11]. However, with higher dosages, other
biochemical alterations may occur such as uncoupling of
oxidative phosphorylation in the electron transport chain
resulting in heat release and stimulation of the respiratory
center in the medulla. A decrease in blood pH will favor for-
mation of lipid-soluble salicylic acid which easily penetrates
the blood brain barrier and undergoes renal reabsorption
[54]. When used therapeutically, aspirin has a high degree
of protein binding which significantly decreases in cases of
overdose and poisoning.
Patients with salicylate toxicity typically present with
tinnitus, gastrointestinal complications (nausea, vomiting,
bleeding, and liver toxicity), hyperthermia (via uncoupling of
oxidative phosphorylation), pulmonary edema, and a mixed
acid-base disorder (high anion gap metabolic acidosis and
respiratory alkalosis via stimulation of respiratory center in
the brainstem) [54, 55].
Recent consensus panel guidelines on themanagement of
severe salicylate toxicity recommend intermittent hemodial-
ysis over other modalities of extracorporeal removal [12].
Hemodialysis should be strongly considered in patients with
an altered mental status (which may be reflective of high
salicylate content in the CNS), pulmonary edema, hypox-
emia, fluid overload states or presence of a medical condition
limiting the administration of sodium bicarbonate (such as
congestive heart failure), presence of either acute or chronic
kidney failure (since it will limit the amount of sodium bicar-
bonate administration and endogenous salicylate clearance),
salicylate levels > 90mg/dL in acute toxicity and normal
renal function and levels > 80mg/dL in acute toxicity, and
impaired renal function and in cases of failure of appropriate
management [12]. A summary of aspirin pharmacokinetics
and the utility of hemodialysis is presented in Table 3.
4.3. Lithium Toxicity. Lithium has been used in the man-
agement of bipolar disorder since the nineteenth century
[56]. The exact mechanism of action of lithium is not clear,
but it may involve modulation of intracellular signaling
pathways [57].Themajor route of lithium elimination is renal
excretion, but it is important to note that about 80%of filtered
lithium is reabsorbed [13].
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Table 2: The features of toxic alcohol poisonings.
Type of toxic
alcohol
Core clinical
features
Core laboratory
features
General principles of
treatment Indications for RRT
Methanol
CNS depression
AMS
Seizures
Visual
changes/retinal
toxicity
Hemodynamic
instability
HAGMA
High osmolal gap
Elevated lactic acid
(formic acid mediated
inhibition of
mitochondrial
electron transport
chain)
Supportive care
Fomepizole
Ethanol (if fomepizole
is unavailable)
Folic acid or folinic
acid
pH < 7.3
Methanol level > 50mg/dL
Visual changes
AKI
Severe electrolyte
derangements
Hemodynamic instability
and progression despite
appropriate care
Ethylene glycol
CNS depression
AMS
Seizures
AKI
Calcium oxaluria
HAGMA
High osmolal gap
Hypocalcemia
Electrolyte
abnormalities
AKI
Calcium oxalate
crystals in the urine
Falsely elevated lactic
acid (glycolic acid can
be mistaken for lactic
acid)
Supportive care
Fomepizole
Ethanol (if fomepizole
is unavailable)
Thiamine
Pyridoxine
pH < 7.3
Ethylene glycol level >
50mg/dL
Glycolic acid level >
8mmol/L
Refractory hyperosmolarity
AKI
Severe electrolyte
derangements
Hemodynamic instability
and progression despite
appropriate care
Diethylene
glycol
CNS depression
AMS
Seizures
AKI
Gastrointestinal
symptoms
Peripheral
neuropathy
HAGMA
High osmolal gap
Elevated liver
enzymes
Supportive care
Fomepizole
Ethanol (if fomepizole
is unavailable)
Thiamine
Pyridoxine
Hemodynamic instability
and progression despite
appropriate care
Persistent HAGMA
Isopropyl
alcohol
CNS depression
AMS
Hemodynamic
instability in
advanced cases
High osmolal gap
Increased ketones in
the blood and urine
Absence of HAGMA
Falsely elevated
creatinine (due to
acetone cross
reactivity)
Supportive care
Fomepizole
Ethanol (if fomepizole
is unavailable)
Hemodynamic instability
and progression despite
appropriate care
Isopropyl alcohol level >
4000mg/dL
CNS: central nervous system.
AMS: altered mental status.
HAGMA: high anion gap metabolic acidosis.
AKI: acute kidney injury.
Lithium has a narrow therapeutic window and is associ-
ated with numerous side effects [57]. Several clinical scenar-
ios of lithium toxicity can occur such as acute overdose in a
suicidal patient, acute on chronic toxicity in patients taking
lithium whose renal function has declined (e.g., patients
with gastroenteritis, decreased oral intake, and patients con-
comitantly taking other medications such as nonsteroidal
anti-inflammatory drugs and angiotensin converting enzyme
inhibitors), and chronic toxicity in patients who slowly
accumulate the medication and develop toxicity [14, 57].
Lithiumwas responsible for 6,610 cases of toxicities including
5 fatalities in the year 2013 [1].
Patients with chronic lithium poisoning typically develop
nephrogenic diabetes insipidus and urinary concentrating
defects, neurologic symptoms (ataxia, tremors, and altered
mental status), hyperparathyroidism, hypothyroidism, and
weight gain [14]. Patients with more acute presentations
tend to have more pronounced gastrointestinal symptoms
such as nausea, vomiting, diarrhea, cardiac arrhythmias, and
neurologic symptoms.
Laboratory findings of acute lithium intoxication may
include a negative anion gap and an osmolal gap [15]. Also
it is important to assess kidney function since acute kidney
insults often precipitate lithium toxicity.
The management of lithium intoxication includes stop-
ping the offending medication, supportive care, and, in
selected cases, renal replacement therapy such as hemodial-
ysis [15]. Hemodialysis should be considered in patients
with lithium levels > 4mEq/L regardless of symptomatology
and in patients with lithium levels > 2.5mEq/L who either
International Journal of Nephrology 7
Table 3: Summary of pharmacological and clearance properties of some pharmacological substances∗.
Substance Molecularweight (daltons)
Protein binding
(%)
Volume of
distribution
(L/kg)
Metabolism and
excretion (%)
Clearance without
hemodialysis
(mL/min)
Clearance with
hemodialysis
(mL/min)
Methanol ∼32 Minimal ∼0.6–0.77
∼95 hepatic
∼2.5 respiratory
∼1 renal
∼11.3 ∼125–215
Ethylene glycol ∼62 Minimal 0.5–0.8 ∼80 hepatic
∼20 renal Up to 27 145–230
Diethylene glycol ∼62 Minimal ∼1 30–50 hepatic50–70 renal Unknown Unknown
Isopropyl alcohol ∼60 Minimal ∼0.45–0.55 80 hepatic20 renal Unknown
∼137 (isopropyl
alcohol)
∼165 (acetone)
Aspirin ∼180
∼49
(∼90 with
therapeutic use
and ∼30 in
overdose)
∼0.15 ∼80 hepatic
∼20 renal 0.6–25 3–100
Lithium ∼74 0 ∼0.3–1 >95 renal 20–40 70–170
Valproic acid ∼144
∼80–90
(continuously
decreases with
higher valproic
acid
concentrations)
∼0.1–0.5 Predominantlyhepatic 5–10 ∼50–90
Metformin ∼129 Minimal ∼1.1 >90 renal ∼7 Up to 170
Dabigatran 471 ∼35 ∼0.85 >80 renal Dependent on renalfunction
Decreases dabigatran
concentration by at
least 40%
∗Adapted from [5–20].
are symptomatic or have some clinical factors (advanced
kidney disease and decompensated congestive heart failure)
limiting the use of intravenous hydration. The end points of
hemodialysis in patients with lithium toxicity are resolution
of clinical symptoms of toxicity and lithium levels < 1mEq/L
[15]. However, it is important to monitor lithium levels after
the cessation of hemodialysis, since lithium tissue stores can
be redistributed into the bloodstream [15, 16]. Most cases of
lithium intoxication treatedwith hemodialysis require at least
a second session of hemodialysis following rebound. This
rebound can be avoided by use of CRRT as described above
preferably after the initial hemodialysis session for rapid
reduction of lithium level [8, 15].
A summary of lithium pharmacokinetics and the utility
of hemodialysis is presented in Table 3.
4.4. Valproic Acid Poisoning. Valproic acid is used for the
management of epilepsy, bipolar disorder, migraine head-
aches, and peripheral neuropathy. The mechanism of action
includes modulation of gamma aminobutyric acid activity
and sodium channel blockade [17]. Valproic acid is a fatty acid
and its toxicity is believed to involve the inhibition of mito-
chondrial beta oxidation [18]. Valproic acid has a favorable
molecular weight and volume of distribution to be cleared by
hemodialysis, though the degree of protein binding is high
at therapeutic concentrations. However, the degree of protein
binding decreases with extra therapeutic concentrations due
to protein saturation, thus making it amenable for hemodial-
ysis [19]. Valproic acid was responsible for 7,776 toxicities
including 2 fatalities in the year 2013 [1].
Clinicalmanifestationsmay include alteredmental status,
tremors, myoclonus, hypotension, tachycardia, and respira-
tory depression [58]. Classic laboratory abnormalities include
hyperammonemia, presence of an osmolal gap, hyperna-
tremia, high anion gap metabolic acidosis, and elevated liver
enzymes.
Management of acute valproic acid intoxication includes
supportive care, administration of naloxone to help against
respiratory depression, and antidote therapy with carnitine
supplementation to offset the inhibitory effects onmitochon-
drial fatty acid oxidation. RRT should be strongly consid-
ered in patients with severe toxicity including those with
cerebral edema (patients with papilledema, focal neurologic
deficits, altered mental status, imaging findings, etc.) and
hemodynamic instability and in those with valproic acid
levels > 1300mg/L. RRT should also be considered in patients
with valproic acid levels > 900mg/L, respiratory depression,
hyperammonemia, and severe metabolic acidosis (pH < 7.1).
Intermittent HD is the preferred modality of RRT in valproic
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acid poisoning. If hemodialysis is not available, then intermit-
tent hemoperfusion or continuous renal replacement therapy
is an acceptable alternative. The end point of hemodialysis
includes clinical stabilization and valproic acid levels <
100mg/L [19]. As in many other cases of intoxication, it is
important to monitor valproic acid levels after the cessation
of hemodialysis, since redistribution of the medication can
cause reemergence of toxicity. A summary of valproic acid
pharmacokinetics and the utility of hemodialysis is presented
in Table 3.
4.5. Metformin Poisoning. Metformin is the most commonly
used oral antihyperglycemic agent worldwide [58]. Besides
treatment of type 2 diabetes mellitus and prediabetes, it
is often used in the management of polycystic ovarian
syndrome [59]. Metformin’s mechanism of action includes
decreased hepatic and intestinal gluconeogenesis, enhanced
glucose utilization, and modulation of mitochondrial oxida-
tion of fatty acids [20, 59]. The majority of overdose cases
occur in patients with renal disease (either acute or chronic),
advanced liver disease, and acute concurrent illness [20].
Metformin was responsible for 8,829 toxicities including 12
fatalities in the year 2013 [1].
The pharmacokinetics of metformin are generally favor-
able for hemodialysis and extracorporeal elimination such
as a low molecular weight and minimal protein binding
except with high volume of distribution [20, 21]. Clinical
manifestations of metformin poisoning are nonspecific and
may include gastrointestinal symptoms such as nausea, vom-
iting, diarrhea, abdominal pain, altered mental status, and
hemodynamic instability. Laboratory features of metformin
poisoning include a high anion gap metabolic acidosis due
to accumulation of lactic acid. The initial mechanism of
lactic acidosis involves modulation of gluconeogenesis [20].
However, later, hemodynamic deteriorationmay underlie the
perpetuation of lactic acidosis.
Treatment of metformin poisoning includes supportive
care and RRT. The low molecular weight, negligible plasma
protein binding, and rapid transport of drug from cells
to serum allow for drug removal by hemodialysis despite
a relatively large VD. It is unclear whether hemodialysis
improves mortality in patients with metformin poisoning.
Furthermore, its efficacy may be suboptimal in patients who
present after tissue redistribution occurs as that leads to
a large volume of distribution. Nevertheless, hemodialysis
should be strongly considered in patients with advanced
renal failure, decompensated congestive heart failure, severe
metabolic acidosis (pH < 7.1), and hemodynamic and clinical
decline despite supportive care [20]. Whenever possible,
prolonged sessions of hemodialysis should be undertaken;
alternatively CRRT can be considered [22]. A summary of
metformin pharmacokinetics and the utility of hemodialysis
is presented in Table 3.
4.6. Dabigatran Poisoning. Dabigatran is a non-vitamin K
oral anticoagulant used in the management of nonvalvular
atrial fibrillation, venous thromboembolism, and postproce-
dural deep venous thrombosis prophylaxis [23]. Dabigatran
represents an alternative to vitamin K antagonists in the vast
majority of patients with the above-mentioned conditions.
Dabigatran is predominantly excreted by the kidneys and
is contraindicated in patients with advanced renal disease
typically defined as creatinine clearance < 30mL/min.
Themajor adverse effect related to the use of dabigatran is
bleedingwhichmay beminor or life-threating, such as in case
of intracranial hemorrhage. Until recently, the management
of bleeding in patients taking dabigatran was supportive [24].
However, recently, amonoclonal antibody, idarucizumab, has
been shown to be effective in themanagement of patientswith
dabigatran related bleeding [25].
Before the availability of idarucizumab, RRT was used in
the bleeding patient taking dabigatran. Several case reports
highlighted the efficacy of RRT in themanagement of patients
with dabigatran related bleeding [26]. In a small study, inter-
mittent hemodialysis enhanced elimination of dabigatran
more efficiently than CRRT, though dabigatran levels may
rebound after cessation of hemodialysis via the effect of
redistribution [27]. Dabigatran levels should be repeated and
repeat hemodialysis should be considered in patients with a
rebound increase in dabigatran concentration. Alternatively,
longer duration hemodialysis sessions or CRRT may be
considered specifically that most patients with dabigatran
toxicity are critically ill with life-threatening bleeding or are
in need for an emergent surgery, where CRRTwould bemore
tolerated. However, it is important that the vast majority of
patients with dabigatran poisoning do not have advanced
renal disease and do not receive renal replacement therapy.
Therefore, a dialysis vascular catheter must be inserted which
may be difficult in an overanticoagulated patient and result in
more bleeding and other complications.Thus, RRT should be
considered in patients with severe bleeding and patients on
dabigatran requiring emergent surgery when idarucizumab
is not available. It is important to note that RRT does not
have a role in the management of other non-vitamin K
anticoagulants.
A summary of dabigatran pharmacokinetics and the
utility of hemodialysis is presented in Table 3.
4.7. Miscellaneous Pharmacologic Poisonings. RRT has been
effective in the management of various medication related
toxicities [28–41, 60–66]. It is important to note that scientific
data is limited to case reports and case series. RRT should
be considered in patients with severe toxicity after failure of
supportive care. A summary of some of these medications
and the role of hemodialysis in the management of these
toxicities is presented in Table 4.
5. Conclusion
The use of RRT should be considered in patients with toxic
alcohol poisoning, salicylate toxicity, lithium overdose, and
metformin poisoning as well as valproic acid toxicity.The role
of RRT in the management of dabigatran toxicity is likely
limited to cases with severe bleeding when idarucizumab
is not available. RRT use should also be considered in the
management of other drug toxicities on a case-by-case basis.
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Table 4: Role of hemodialysis in the management of miscellaneous pharmacological poisonings.
Medication Therapeutic use Classic toxicity Treatment Efficacy of hemodialysis (HD)
Carbamazepine
Epilepsy
Trigeminal neuralgia
Bipolar disorder
Altered mental status
Seizures
Hemodynamic
instability
Arrhythmias
Supportive May reduce carbamazepine levelby about 50% [21–23]
Phenobarbital Epilepsy Altered mental status Supportive
May reduce phenobarbital level
by up to 59% after 4 h HD
[24–26]
Phenytoin EpilepsyCardiac arrhythmias
Horizontal nystagmus
Ataxia
Altered mental status
Arrhythmias
Hypersensitivity
reactions
Supportive
Should be considered in patients
with severe poisoning not
responding to supportive care
[27]
Baclofen Spasticity
Muscle hypotonia
Altered mental status
Hemodynamic
instability
Supportive
Conventional HD can decrease
the concentration by up to 79%
[28–30]
Eptifibatide
Antiplatelet agent
Acute coronary
syndrome
Bleeding
Supportive
Platelet
transfusion
Limited to patients with renal
failure experiencing ongoing
severe bleeding not responding
to supportive care [31]
Diltiazem
Atenolol
Hypertension
Cardiac arrhythmias
Bradycardia
Hemodynamic
instability
Supportive
HD may be considered in
unstable patient with renal
failure not responding to
supportive care [32, 33]
Lisinopril
Hypertension
Heart failure
Renal disease
Acute kidney injury
Hyperkalemia
Hemodynamic
instability
Angioedema
Supportive
HD may be considered in
unstable patient with renal
failure not responding to
supportive care [34]
Theophylline Obstructive pulmonarydisease
Arrhythmias
Altered mental status
Seizures
Supportive
HD may be considered in
unstable patient with renal
failure not responding to
supportive care [35, 36]
Cefepime Antibiotic NeurotoxicityAltered mental status Supportive
HD may be considered in
unstable patient with renal
failure not responding to
supportive care [37]
Metronidazole Antibiotic
Altered mental status
Seizures
Neuropathy
Gastrointestinal
symptoms
Supportive
HD should be considered in
patient with metronidazole
overdose and renal failure [38]
Dapsone Antibiotic
Hypersensitivity
reactions
Methemoglobinemia
Supportive
Methylene blue
HD should be considered in
patients not responding to
conventional therapy [39]
Isoniazid Antibiotic
Neurotoxicity
Seizures
Liver toxicity
Supportive
Pyridoxine
HD should be considered in
patients not responding to
conventional therapy [40]
Acetaminophen Analgesic Liver failure
Supportive
N-
Acetylcysteine
Liver transplant
HD may be considered in
unstable patients with metabolic
acidosis [41]
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Additional Points
Why is this topic important? It critically reviews the scien-
tific literature on the management of pharmacological tox-
idromes. What does this review attempt to show? It attempts
to show the role of hemodialysis in the management of
pharmacological poisonings. What are the key findings?
Hemodialysis should be strongly considered in patients with
toxic alcohol ingestion, salicylate overdose, severe valproic
acid toxicity, metformin overdose, and lithium poisoning.
Hemodialysis should be considered on case-by-case basis in
the management of toxidromes secondary to other pharma-
cological agents. How is patient care impacted? Hemodialysis
in the management of various pharmacological toxidromes
which can be fatal should be considered. Early consulta-
tion with nephrologist regarding hemodialysis initiation is
advised.
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